NCT06597565View on ClinicalTrials.gov

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

August 23, 2028

Study Completion Date

August 23, 2028

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Gemcitabine

Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368.

DRUG

ACR-368

ACR-368 is an experimental drug.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Acrivon Therapeutics
All Listed Sponsors
collaborator

Acrivon Therapeutics

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06597565 - A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Biotech Hunter | Biotech Hunter